Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Watch Kyle Zingaro, UCB’s Head of Gene Therapy Process Sciences, discuss our ambition to deliver life-changing therapies to patients by strengthening our #GeneTherapy team. Interested in joining us? Find out more: https://t.co/wkfuD3uIAa #UCBcareers
— UCB News (@ucb_news) 30.11.2021 -
Take the #AdvantageHers questionnaire today, designed to support women be in control of their chronic inflammatory disease. Access the questionnaire and resources to help throughout the disease journey https://t.co/LZh4PmO2Sz
— UCB News (@ucb_news) 29.11.2021 -
At UCB, we use our minds to push the boundaries of science with the aim of delivering life-changing solutions for patients. Hear more about what it’s like to work at #UCB from our #GeneTherapy team and find out more about our opportunities #rdjobs https:
— UCB News (@ucb_news) 23.11.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
